S&P 500
7,240.20
+0.19%
Dow Jones
49,562.10
+0.14%
Nasdaq 100
27,761.20
+0.27%
Russell 2000
2,816.61
+0.42%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,633.00
+0.63%

Health and Healthcare

OncoGenex Prices Secondary Offering, Shares Fall (OGXI)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Cancer therapy developer OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI) has priced a secondary offering of 4.165 million common shares at $12.00/share, a discount of 31% to yesterday’s closing price of $17.43. Needless to say the shares are getting pounded today.

OncoGenex expects to realize about $46.8 million from the offering, net of fees and expenses. Leerink Swann LLC and Stifel Nicolaus Weisel are acting as joint book-running managers and Lazard Capital Markets LLC and William Blair & Company, L.L.C. are acting as co-managers. The underwriters have a 30-day over-allotment option of 624,750 shares.

The company did not specify how it plans to use the proceeds from the sale.

Shares are down nearly -20% at $13.99 in a 52-week range of $8.63-$18.99.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Jon C. Ogg |

Top Active Trader Alert Stocks (ABK, AAPL, ARMH, CTIC, CWTR, INFN, MSFT, OGXI)

Active traders and day traders have many stocks to choose from this Wednesday morning.  We are tracking news and moves…
6 Biotechs Seriously on the Move
Chris Lange |

6 Biotechs Seriously on the Move

A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as…
Paul Ausick |

Busiest IPO Week of the Year: 14 Companies on the Calendar

ThinkstockFour of last week’s six initial public offering (IPO) candidates successfully launched into the public equity markets, but the reception…
4 Biotech IPOs Hoping to Become First U.S. IPO of 2016
Paul Ausick |

4 Biotech IPOs Hoping to Become First U.S. IPO of 2016

To say that the month of January was a bust for initial public offerings (IPOs) is an understatement. January was…
Week of November 9 Sees 9 IPOs on the Calendar
Paul Ausick |

Week of November 9 Sees 9 IPOs on the Calendar

Two holdovers and seven new entries are on the coming week's IPO calendar, including four biotechs and two financial companies.
Paul Ausick |

Health Care Dominates IPO Schedule for First Week of February

Including one holdover from last week, there are 12 IPOs on the calendar for the first week of February.
3 New Biotech IPOs on Calendar for Next Week
Paul Ausick |

3 New Biotech IPOs on Calendar for Next Week

Blank-check company KLR Energy Acquisition Corp. (NASDAQ: KLREU) completed its initial public offering (IPO) last Friday, the first successful IPO…
Paul Ausick |

8 IPOs on the Calendar for Week of July 13

The initial public offering (IPO) calendar heats up again in the week of July 13, with eight offerings scheduled to…
Paul Ausick |

7 Health Care IPOs on Next Week’s Calendar

ThinkstockLast week was not a standout for initial public offerings (IPOs). There were three on the calendar, and only a…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618